Based on the Arbutus Biopharma Corp stock forecast from 3 analysts, the average analyst target price for Arbutus Biopharma Corp is USD 5.00 over the next 12 months. Arbutus Biopharma Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arbutus Biopharma Corp is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Arbutus Biopharma Corp’s stock price was USD 3.17. Arbutus Biopharma Corp’s stock price has changed by -9.69% over the past week, -4.23% over the past month and +6.38% over the last year.
No recent analyst target price found for Arbutus Biopharma Corp
No recent average analyst rating found for Arbutus Biopharma Corp
Company Overview Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Read Less
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product can...Read More
Frequently Asked Questions About Arbutus Biopharma Corp (ABUS) Stock
Based on ratings from 3 analysts Arbutus Biopharma Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on ABUS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ABUS is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on ABUS's stock to indicate if its overvalued.
The last closing price of ABUS's stock was USD 3.17.
The most recent market capitalization for ABUS is USD 0.62B.
Based on targets from 3 analysts, the average taret price for ABUS is projected at USD 5.00 over the next 12 months.
This means that ABUS's stock price may go up by +57.73% over the next 12 months.
We can't find any ETFs which contains Arbutus Biopharma Corp's stock.
As per our most recent records Arbutus Biopharma Corp has 73 Employees.
Arbutus Biopharma Corp's registered address is 701 Veterans Circle, Warminster, PA, United States, 18974.
You can get more information about it from Arbutus Biopharma Corp's website at https://www.arbutusbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Arbutus Biopharma Corp (ABUS) Stock
Based on ratings from 3 analysts Arbutus Biopharma Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on ABUS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ABUS is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on ABUS's stock to indicate if its overvalued.
The last closing price of ABUS's stock was USD 3.17.
The most recent market capitalization for ABUS is USD 0.62B.
Based on targets from 3 analysts, the average taret price for ABUS is projected at USD 5.00 over the next 12 months.
This means that ABUS's stock price may go up by +57.73% over the next 12 months.
We can't find any ETFs which contains Arbutus Biopharma Corp's stock.
As per our most recent records Arbutus Biopharma Corp has 73 Employees.
Arbutus Biopharma Corp's registered address is 701 Veterans Circle, Warminster, PA, United States, 18974.
You can get more information about it from Arbutus Biopharma Corp's website at https://www.arbutusbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ABUS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
